2X1:ETR
Abivax SA
78,30 €
arrow_downward
-0,89%(-0,70) 1D
12 tet, 10:00:00 p.d., GMT+2 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 2X1...
Hap
79,25 €
I lartë
79,25 €
I ulët
78,30 €
Kapitalizimi i tregut
6,85 mld
Vëllimi mesatar
1,81 mijë
Vëllimi
112,00
Maksimumi 52-javor
137,40 €
Minimumi 52-javor
60,85 €
Fitimet për aksion
-5,20 €
Numri i punonjësve
98
Hap
79,25 €
I lartë
79,25 €
I ulët
78,30 €
Kapitalizimi i tregut
6,85 mld
Vëllimi mesatar
1,81 mijë
Vëllimi
112,00
Maksimumi 52-javor
137,40 €
Minimumi 52-javor
60,85 €
Fitimet për aksion
-5,20 €
Numri i punonjësve
98
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
TradingView
·
3 ditë më parë
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside
Profili
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Rreth Abivax SA
Drejtori ekzekutivMarc de Garidel | Hartmut J. Ehrlich
Punonjësit98
Themeluar më4 dhj 2013
Selia-
Sektori-
Uebsajtiabivax.com